🔗 Share this article

As the United States undertakes historic revisions to its immunization guidelines, an unexpected name has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning Covid shots throughout the global health crisis and has concentrated on potential deaths following COVID-19 vaccination in her short position at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Program

Public health authorities planned to announce radical changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of step with a large portion of the world with little proof for public health gain. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

Consolidating Power at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date statements, she has kept her attention on vaccines – usually the purview of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Questions Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “understand laws and regulations and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the kind of background that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the generic drug division approves thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and each of these have to be managed,” Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant administrative aspect to the role, which manages over 5,000 employees. “It’s a enormous leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Programs

When asked about inquiries about Høeg’s qualifications and whether this assignment signifies greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on inaccurate assumptions”.

“Her resume matches the functions of her role,” the spokesperson explained, citing the period Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s controversial priority voucher program, a contentious expedited medication authorization process that reportedly worried her predecessors. “How are these drugs being picked for this voucher program? Who is making the choices?” Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the agency appears to be shifting towards less stringent oversight of most medications, aside from vaccines.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more documented, if troubling, history, some experts have noted. She released a analysis using unconfirmed volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the incoming federal leadership included altering regulations for new vaccines and halting “optional” vaccines, she said after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested excluding adolescent males from getting Covid vaccines.

“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to accommodate the science in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of other skeptics, {like|